Jennifer Postelnek
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, T-cell and B-cell Immunology, Multiple Myeloma Research and Treatments, Chemokine receptors and signaling, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents(2012)140 cited
- → Selective Itk Inhibitors Block T-Cell Activation and Murine Lung Inflammation(2004)112 cited
- → Suppression of Glomerulonephritis in Lupus‐Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase(2013)82 cited
- → Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors(2018)63 cited
- → Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis(2005)42 cited
- → Novel Pyrrolidine Ureas as C−C Chemokine Receptor 1 (CCR1) Antagonists(2009)24 cited
- → A HIGHLY SELECTIVE INHIBITOR OF IκB KINASE, BMS-345541, AUGMENTS GRAFT SURVIVAL MEDIATED BY SUBOPTIMAL IMMUNOSUPPRESSION IN A MURINE MODEL OF CARDIAC GRAFT REJECTION(2004)23 cited
- → Novel pyrrolidine heterocycles as CCR1 antagonists(2010)14 cited
- → Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab(2016)9 cited
- → Fit-for-purpose protein biomarker assay validation strategies using hybrid immunocapture-liquid chromatography-tandem-mass spectrometry platform: Quantitative analysis of total soluble cluster of differentiation 73(2020)7 cited